TORONTO (May 11, 2016) – Johnson & Johnson Innovation LLC, today announced the opening of JLABS @ Toronto, a new 40,000-square-foot life sciences incubator, providing entrepreneurs shared lab space and…
Partners for JLABS @ Toronto include Janssen Inc., MaRS Innovation and seven of MI's 15 member institutions TORONTO, Sept. 8, 2015 — The Ontario Government, University of Toronto, and MaRS…
MaRS Innovation today announced that Johnson & Johnson Innovation has expanded its collaboration with MaRS Innovation to identify and advance early-stage technologies of interest. The announcement was made in advance…
TORONTO, Jan. 12, 2015 — MaRS Innovation, the commercialization agent for Ontario's 15 leading academic institutions, today announced that it has formed a research collaboration with Johnson & Johnson Innovation,…
Johnson & Johnson Innovation and its affiliate Janssen Inc. in Canada announced new collaborations with two Canadian early-stage drug technology development centres, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify…
Collaboration will advance early-stage technologies and identify high-potential opportunities related to human health TORONTO, Nov. 25, 2013 - MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, today announced a new collaboration…
MaRS Innovation (MI) has signed a co-funding agreement with the Johnson & Johnson Corporate Office of Science and Technology to capitalize and accelerate the use of Toronto-based life sciences technologies during the…
AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care November 28th, 2023 Press Release Toronto, ON — AmacaThera, a leader in the development…
Michael Wasserman, Ph.D., is a Partner and COO of Elevage Medical Technologies. Michael has over 30 years of experience in healthcare as a scientist, entrepreneur, executive, and investor. Prior to…
Toronto, ON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that…
Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca